Don't tell anyone but despite all the razzmatazz the human genome sequence is not complete. In fact it is only a 'working' draft. There is a great deal more work to be done to obtain a complete view of the human genome as the sequences of only two human chromosomes -21 and 22 -are effectively in the same state as the other genomes that have been sequenced so far (Dunham et al. 1999; Hattori et al., 2000) .
But alongside the sequencing work, structural genomics, described as determining the three-dimensional structure of proteins in parallel rather one at a time, has been boosted by several technical advances, not the least of which is access to genome sequences from a growing list of species.
Protein structures can be very illuminating from a biochemical perspective and as more protein structures are determined the more useful they will be. One of the most recent highlights in structural biology is the high-resolution analysis of the ribosome (Nissen et al., 2001 , but also see Hendrickson, 2001 for other important structures).
Being able easily to solve the structure of proteins is also very important for drug discovery. Several drugs, such as inhibitors of the influenza virus and HIV, were discovered by systematic analysis of the molecular interactions between the potential drug and target protein.
The mechanism of action of a new inhibitor of c-Abl kinase -STI-571 -was also deduced from a co-complex of inhibitor and enzyme (Schindler et al., 2000) .
Much has been made of the rivalry -which still continuesbetween the efforts of the public domain and the private sector in sequencing the human genome. Being in the private sector, I was rather looking forward to comparing the papers describing the 'working drafts' of the human genome. I have to say I was somewhat disappointed. Despite the enormity of the task and the technical sophistication of the approaches, seeing our own human genome sequence in print just did not do it for me. I don't know whether it was the way the papers were written or the fact that such a small proportionless than 5% -of the genome coded for proteins that was the problem. Perhaps it was because it was all rather dense and essentially not complete. I expect the mouse genome sequence to be more interesting. This sequence will certainly increase the accuracy of assigning exons to mammalian genes and comparative genomics is by its very nature more revealing (see Rubin et al., 2000) .
Even though the two draft human sequences are similar, the interpretation of them in the papers from the two groups was rather different. In the 'public' paper (International Human Genome Consortium, 2001) there was an accent on repeats and genome evolution while in the 'commercial' paper (Venter et al., 2001) there was more of a concentration on coding DNA. There were, for example, useful tables telling us how many genes there are coding for proteins in different families. There are thought now to be over 600 G-protein coupled receptors (GPCRs). For those interested in the human genome sequence from a drug discovery point of view this is important information. It is now a requirement to know how many proteins there are in those families that are already known to contain drug targets. GPCRs are the target for about 50% of all small molecule drugs. Other important families include nuclear hormone receptors, ion channels, phosphodiesterases, and protein kinases.
As has been pointed out by many genome watchers, the conclusion that there are only 35,000 genes in the human genome when compared to the less complex organisms -19,000 in worm, 14,000 in fly and 7,000 in yeast -is surprising. But even now, new genes are being found in these genomes so it is still an open question of how many genes there actually are.
One resource that would help would be to have comprehensive collections of full-length human cDNAs such as those being assembled for the mouse in Japan (RIKEN, 2001) . Some of these genes, via alternative splicing, will code for multiple protein products: the precise relationship between number of genes and number of encoded proteins will take some effort to find out. We are also some time away from being able to do a simple database look-up to find genes in chromosomal regions involved with susceptibility to disease, or any other complex trait, and it is still very difficult to find these regions.
Features

Unfolding the genomes' structural secrets
Genomes: Publication of the first draft of the human genome sequence has raised as many questons as answers for some researchers, but Tim Harris looks forward to the details of protein structures that may now be gleaned using newly developed automated approaches.
From a protein structure perspective the number of genes in all these organisms is still, however, large. There are something in the order of 15,000 protein structures in the Protein Data Bank, but only some 3,000 of these are unique (Berman et al., 2000) . There are, for example, hundreds of versions of lysozyme in the database and there are many thousands of proteins for which there are no structural data at all. Only about 30% of the protein sequences in SwissProt can be assigned to a structural class on the basis of sequence homology to one of these structural templates. One of the goals of the structural genomics initiatives is to provide templates for the majority of protein sequences (Sanchez et al., 2000) .
A question for the structural biologist analogous to the sequencers' 'How many genes are there in the genome?' might be 'How many protein folds are there?'. One of the objectives of structural genomics research is to be able to relate more directly specific amino acid sequences with protein folds. Eventually, when there are a great deal more real structures available, it will be possible to predict structures more easily from primary amino acid sequence (Thornton et al., 2000) .
There is an analogy between the development of DNA sequencing and X-ray crystallography that I was reminded of while reading the genome papers. DNA sequencing is based on technology developed by Fred Sanger over 25 years ago. By a series of major changes, the most important of which, from a throughput point of view, was access to compute power and the move from slab to capillary gels, DNA sequencing went from a laboratory technique to a high throughput process. Similar things are happening in X-ray crystallography.
Eight years ago structure determination was a slow and laborious process. The advent of simple gene cloning techniques and access to many gene sequences has allowed the approach of choosing the same gene from several species as the starting point to increase the chances of obtaining a soluble protein for X-ray analysis, an approach pioneered by Structural GenomiX. Proteins can be labeled with histidine tags and rapid affinitybased methods used for protein purification. Automation technology can then be used for rapid crystallization set up and viewing, allowing the production of hundreds of protein crystals (Abola et al., 2000; Edwards et al., 2001 ).
The first publication of the complete structural proteome of any organism will be an interesting read
In the past, structure determination was carried out using heavy metal derivatives to solve the phase problem and allow the interpretation of the diffraction patterns. Now, with access to much higher energy synchrotron radiation at third generation sites, multi-wavelength anomalous diffraction (MAD) phasing methods can be used (Hendrickson et al., 1989) . Proteins are generally labeled during synthesis with selenomethionine for this purpose. Instead of taking days to collect decent data sets, sufficient information to derive a three-dimensional protein structure can be collected in a few hours or less. And, as in sequencing, the new computational power available has speeded up the process of going from diffraction pattern to electron density to structure. Indeed some of this can now be completed automatically. The job of the X-ray crystallographer, like the DNA sequencer, is no longer the 'doing it' but the interpretation of what has been done. Even more complicated transmembrane proteins may yield to this kind of structural genomics approach. Structural genomics will do several things for us. By allowing the determination of structures much more rapidly than before one can imagine being able not only to get a clearer view of fold space but also get structures of many proteins in the same family.
From a drug discovery perspective it is very important to obtain the structure of many members of a closely related family of proteins because it will be possible to get a three-dimensional view of many compounds bound to both the target protein in the family and all the relatives, some of which may mediate undesirable, rather than therapeutic effects.
Another relevant application would be to obtain systematically the structure of proteins that are coded for by open reading frames of no known function. As the structure databases increase in size and the correlation between structure and function becomes clearer it may be possible to assign function to unknown proteins by virtue of their structure and cross-referencing to databases of gene expression, protein-protein interaction and gene deletion information (see Vidal, 2001) The first publication of the complete structural proteome of any organism will be an interesting read: for the human genome it would be just plain beautiful but that vista is unlikely to be viewed for a little while yet.
